138 related articles for article (PubMed ID: 26902992)
1. The role of danger signals and ectonucleotidases in acute graft-versus-host disease.
Apostolova P; Zeiser R
Hum Immunol; 2016 Nov; 77(11):1037-1047. PubMed ID: 26902992
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Advances in understanding the pathogenesis of graft-versus-host disease.
Magenau J; Runaas L; Reddy P
Br J Haematol; 2016 Apr; 173(2):190-205. PubMed ID: 27019012
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
5. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of urate oxidase in the reduction of acute graft-versus-host disease after myeloablative allogeneic stem cell transplantation.
Yeh AC; Brunner AM; Spitzer TR; Chen YB; Coughlin E; McAfee S; Ballen K; Attar E; Caron M; Preffer FI; Yeap BY; Dey BR
Biol Blood Marrow Transplant; 2014 May; 20(5):730-4. PubMed ID: 24530972
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses.
Maeda Y
Int J Hematol; 2013 Sep; 98(3):293-9. PubMed ID: 23982970
[TBL] [Abstract][Full Text] [Related]
8. [Graft versus host disease and cytokines].
Itoh T
Nihon Rinsho; 2003 Sep; 61(9):1504-11. PubMed ID: 14515716
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-host disease.
Choi S; Reddy P
Panminerva Med; 2010 Jun; 52(2):111-24. PubMed ID: 20517195
[TBL] [Abstract][Full Text] [Related]
10. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
Kline J; Subbiah S; Lazarus HM; van Besien K
Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
[TBL] [Abstract][Full Text] [Related]
11. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
12. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
13. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Duran-Struuck R; Reddy P
Transplantation; 2008 Feb; 85(3):303-8. PubMed ID: 18301323
[TBL] [Abstract][Full Text] [Related]
14. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation.
Elmaagacli AH; Koldehoff M; Hindahl H; Steckel NK; Trenschel R; Peceny R; Ottinger H; Rath PM; Ross RS; Roggendorf M; Grosse-Wilde H; Beelen DW
Transplantation; 2006 Jan; 81(2):247-54. PubMed ID: 16436969
[TBL] [Abstract][Full Text] [Related]
15. The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease.
Apostolova P; Zeiser R
Front Immunol; 2016; 7():439. PubMed ID: 27818661
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
17. Progress and prospects: graft-versus-host disease.
Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
[TBL] [Abstract][Full Text] [Related]
18. Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease.
Zitzer NC; Garzon R; Ranganathan P
Front Immunol; 2018; 9():2561. PubMed ID: 30455702
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.
Bleakley M; Turtle CJ; Riddell SR
Expert Rev Hematol; 2012 Aug; 5(4):409-25. PubMed ID: 22992235
[TBL] [Abstract][Full Text] [Related]
20. Danger signals activating innate immunity in graft-versus-host disease.
Zeiser R; Penack O; Holler E; Idzko M
J Mol Med (Berl); 2011 Sep; 89(9):833-45. PubMed ID: 21573893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
